N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed
- PMID: 17691920
- DOI: 10.2174/138920007781368908
N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed
Abstract
In recent years several arylpiperazine derivatives have reached the stage of clinical application, mainly for the treatment of depression, psychosis or anxiety. Examples are the pyrimidinylpiperazine buspirone, the chlorophenylpiperazine derivatives nefazodone and trazodone, the dichlorophenylpiperazine aripiprazole and the benzisothiazolyl derivatives perospirone and ziprasidone. Most of them undergo extensive pre-systemic and systemic metabolism including CYP3A4-dependent N-dealkylation to 1-aryl-piperazines. These metabolites are best known for the variety of serotonin receptor-related effects they cause in man and animals, although some have affinity for other neurotransmitter receptors; others, however, are still largely unexplored despite uncontrolled use as amphetamine-like designer drugs. Once formed they distribute extensively in tissues, including brain which is the target site of most arylpiperazine derivatives, and are then primarily biotransformed by CYP2D6-dependent oxidation to hydroxylates which are excreted as conjugates; only 1-(2-benzisothiazolyl)-piperazine is more susceptible to sulfur oxidation than to aromatic hydroxylation. In studies analysing animal brain and human blood, 1-aryl-piperazine concentrations were either higher or lower than the parent compound(s), although information is available only for some derivatives. At steady state, the metabolite-to-parent drug ratios varied widely among individuals taking the same dosage of the same arylpiperazine derivative. This is consistent with the known individual variability in the expression and activity of CYP3A4 and CYP2D6. This review also surveys current published information on physiological and pathological factors affecting the 1-aryl-piperazine-to-parent drug ratios and examines the potential role of 1-aryl-piperazine formation in the pharmacological actions of the arylpiperazine derivatives that are already or will shortly be available in major markets.
Similar articles
-
In-vivo metabolism of 4-substituted arylpiperazines to pharmacologically active 1-arylpiperazines.Boll Chim Farm. 1990 May;129(5):183-9. Boll Chim Farm. 1990. PMID: 1982054 Review.
-
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.Drugs. 2004;64(15):1715-36. doi: 10.2165/00003495-200464150-00010. Drugs. 2004. PMID: 15257633 Review.
-
Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone.J Anal Toxicol. 2003 Nov-Dec;27(8):560-8. doi: 10.1093/jat/27.8.560. J Anal Toxicol. 2003. PMID: 14670134
-
Biotransformation of post-clozapine antipsychotics: pharmacological implications.Clin Pharmacokinet. 2000 May;38(5):393-414. doi: 10.2165/00003088-200038050-00002. Clin Pharmacokinet. 2000. PMID: 10843459 Review.
-
Lipophilicity and disposition of 1-aryl-piperazines in the rat.Xenobiotica. 1987 May;17(5):605-16. doi: 10.3109/00498258709043967. Xenobiotica. 1987. PMID: 3604264
Cited by
-
LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor.Neurosci Lett. 2010 Aug 30;481(1):12-6. doi: 10.1016/j.neulet.2010.06.036. Epub 2010 Jun 23. Neurosci Lett. 2010. PMID: 20600619 Free PMC article.
-
Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Paediatr Drugs. 2013 Jun;15(3):217-33. doi: 10.1007/s40272-013-0024-6. Paediatr Drugs. 2013. PMID: 23588704 Review.
-
Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs.J Clin Med. 2022 Mar 22;11(7):1758. doi: 10.3390/jcm11071758. J Clin Med. 2022. PMID: 35407366 Free PMC article.
-
The Therapeutic Potential of 2-{[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles as Ligands for Alpha1-Adrenergic Receptor - Comparative In Silico and In Vitro Study.Appl Biochem Biotechnol. 2022 Aug;194(8):3749-3764. doi: 10.1007/s12010-022-03922-8. Epub 2022 May 4. Appl Biochem Biotechnol. 2022. PMID: 35507251
-
Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors.J Med Chem. 2010 Oct 28;53(20):7344-55. doi: 10.1021/jm100925m. J Med Chem. 2010. PMID: 20873719 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources